If all goes to plan, ANGLE’s Parsortix cancer-detecting blood test could get the green light from US regulators in early 2020, and bosses are strengthening the balance sheet ahead of that
Original Article: ANGLE raises £18mln as it gears up for Parsortix commercialisation